| Literature DB >> 33488599 |
Lili Li1,2, Jie Li3, Meiling Gao1,2,3, Huimin Fan1,2, Yanan Wang4, Xin Xu1,2, Chunfeng Chen4, Junxiao Liu1,2, Jocelyn Kim5, Roghiyh Aliyari5, Jicai Zhang3, Yujie Jin3, Xiaorong Li1,2, Feng Ma1,2, Minxin Shi6, Genhong Cheng5, Heng Yang1,2.
Abstract
The widespread prevalence of coronavirus disease-2019 (COVID-19) which is caused by severe respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has resulted in a severe global public health emergency. However, there are no sensitive biomarkers to predict the disease prognosis of COVID-19 patients. Here, we have identified interleukin-8 (IL-8) as a biomarker candidate to predict different disease severity and prognosis of COVID-19 patients. While serum IL-6 become obviously elevated in severe COVID-19 patients, serum IL-8 was easily detectible in COVID-19 patients with mild syndromes. Furthermore, lL-8 levels correlated better than IL-6 levels with the overall clinical disease scores at different stages of the same COVID-19 patients. Thus, our studies suggest that IL-6 and IL-8 can be respectively used as biomarkers for severe COVID-19 patients and for COVID-19 disease prognosis.Entities:
Keywords: biomarker; coronavirus disease-2019 prognosis; cytokine serum profile; cytokine storm; interleukin-6; interleukin-8; respiratory syndrome coronavirus 2
Mesh：
Substances：
Year: 2021 PMID： 33488599 PMCID： PMC7820901 DOI： 10.3389/fimmu.2020.602395
Source DB: PubMed Journal: Front Immunol ISSN： 1664-3224 Impact factor: 7.561